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OBJECTIVE: To evaluate the safety and effectiveness of trabeculectomy with mitomycin C in the management of childhood 
glaucoma.
INTRODUCTION: The use of antifibrotic agents enhances the success of trabeculectomy performed in both adults and chil-
dren. 
METHODS: A retrospective chart review (1991-2001) of 114 patients (114 eyes) from 0-14 years of age with congenital or de-
velopmental glaucoma. These patients underwent trabeculectomy with mitomycin but had not been previously treated with any 
antifibrotic agent. 
RESULTS: The mean patient age was 57.36 +/- 51.14 months (range: 0.5-168 months). Treatment was considered successful in 
63 eyes (55.26%), with a mean intraocular pressure of 12.11 +/- 3.98 mmHg. For patients categorized as successfully treated, the 
mean follow-up time was 61.16 +/- 26.13 months (range 12-113 months). A post-surgical intraocular pressure of < 16 was observed 
in 47 eyes. The life-table success rates for intraocular pressure control at 24, 36, 48, and 60 months were 90.2%, 78.7%, 60.7% and 
50.8%, respectively. The cumulative probability of failure was 40.8% at 12 months. Following surgery, endophthalmitis appeared 
in eight eyes (4.88%) after an average 36.96 months (range: 1.7-106 months). Other complications included expulsive hemorrhage, 
flat anterior chamber and bleb leak.
DISCUSSION: It has been reported in pediatric patients that trabeculectomy without adjunctive antimetabolites achieves a suc-
cessful outcome in 30% to 50% of cases. In our study, treatment was considered successful in 63 eyes (55.26%) within 61.16 
+/- 26.13 months of follow-up.
CONCLUSIONS: Trabeculectomy with mitomycin is safe and effective for short-term or long-term treatment of congenital or 
developmental glaucoma. The frequency of bleb-related endophthalmitis was no higher in these patients than that described in 
adults.
KEYWORDS: Trabeculectomy. Childhood glaucoma. Mitomycin. Complications. Efficacy.
INTRODUCTION 
Congenital glaucoma is a major cause of blindness in 
children, despite its low incidence (1:10,000 births).1 Its 
management is primarily surgical, with trabeculotomy 
and goniotomy being the procedures of first choice in the 
majority of cases of primary congenital glaucoma.2-4 If 
intraocular pressure is not adequately controlled by these 
procedures, trabeculectomy is usually the next course of 
action. The success rate of trabeculectomy in primary 
congenital glaucoma varies. Most series achieve a success 
rate of 35-85%, depending on the number of previous 
surgeries, the length of follow-up and the population 
studied.5-9
The success of trabeculectomy performed in adults 
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or children is enhanced by the use of antifibrotic agents, 
which suppress fibroblast activity.10-16 A study with a shorter 
follow-up reported a success rate of 67% using intraoperative 
mitomycin C as an adjunctive therapy to trabeculectomy 
performed for the treatment of congenital or developmental 
glaucoma.17
To the best of our knowledge, this study reports a larger 
series and a longer follow-up than any previous study of 
trabeculectomy and adjunctive mitomycin treatment of 
childhood glaucoma.
The purpose of this manuscript is to evaluate the safety 
and effectiveness of trabeculectomy with mitomycin C in the 
management of childhood glaucoma.
MATERIALS AND METHODS 
We reviewed charts (1991-2001) of 125 patients who 
ranged from 0-14 years old at the time of diagnosis and 
surgery. All had presented with primary congenital glaucoma 
or glaucoma associated with other developmental anomalies, 
and all were treated with trabeculectomy and adjunctive 
intraoperative mitomycin C. Cases in which any antifibrotic 
agent, including mitomycin, had been used in any prior 
surgery were excluded.
All eyes in which mitomycin C was used had poor 
surgical prognoses, including those of patients at a very 
young age, patients with aphakia and patients with multiple 
previous glaucoma procedures. This study included some 
cases in which trabeculotomy, goniotomy or trabeculectomy 
without antimetabolites had failed previously. Patients who 
had not undergone surgery but had a corneal diameter of 
> 14 mm, as well as patients with other developmental 
glaucomas such as Peter’s anomaly, Sturge-Weber syndrome, 
congenital aniridia or Axenfeld-Rieger (AR) disease, were 
also included.
All surgeries were performed by one of two authors, 
both using the same technique. Briefly, after a limbal-based 
conjunctival flap was prepared, a 2 X 3 mm rectangular scleral 
flap of one-third to one-half of the scleral thickness was cut 
toward the clear cornea. The incision was made in the superior 
portion of the globe. A solution of 0.2 mg/mL mitomycin 
C was prepared, and a 4 x 4 mm surgical sponge soaked in 
the solution was held in contact under the scleral flap, with 
conjunctival/Tenon laid over it, for five minutes. After that, the 
entire area was irrigated with 40 mL of saline solution. The 
procedure was then completed as a standard trabeculectomy. 
However, some minor modifications were made: sclerectomy 
was performed using a number-11 blade. Iridectomy was not 
performed in any case because these eyes had a very deep 
anterior chamber and there was a low risk of internal blockage. 
The scleral flap was sutured more securely than usual, using 
a 10-nylon suture. The conjunctival/Tenon layer was sutured 
with slightly more tissue enclosed in each stitch. Topical 
cycloplegics, steroids and antibiotics were administered post-
operatively. Other than digital massage, no manipulations 
(such as bleb revision or suturelysis) were performed unless 
deemed absolutely necessary. Hypotensive drugs were utilized 
only when the target-pressure was not achieved.
Intraocular pressure was measured before and after 
surgery using a Goldman tonometer. When necessary, 
children were sedated with chloral hydrate syrup (25-50 mg/
kg body weight) for the measurement of intraocular pressure. 
As some of the patients had some degree of corneal opacity 
that prevented the adequate evaluation of the optic disc, only 
intraocular pressure was analyzed.
The clinical evaluation of the results included the 
determination of intraocular pressure and the identification 
of any unexpected complications.
Eyes with an intraocular pressure between 5 and 21 mmHg 
after surgery with or without the use of medication were 
considered successfully treated. If the intraocular pressure 
remained under 21 mmHg without the use of any medication, 
the treatment was considered an absolute success. Eyes with 
an intraocular pressure greater than 21 mmHg at the last visit 
or eyes with complications (phthisis, retinal detachment or 
endophthalmitis) were considered a failure.
The end-point of the study was either the final visit (after 
at least one year of follow-up), when the patient needed 
a subsequent operation to control intraocular pressure or 
when the patient developed any other complications, such as 
phthisis bulbi, retinal detachment or endophthalmitis.
To evaluate the efficacy of the procedure, when a patient 
had surgery on both eyes, one eye was randomly selected to 
be evaluated for this study. To assess safety, we considered 
all surgeries performed without randomization. 
Surgical outcome was evaluated using cumulative 
probability life-table analysis (Kaplan-Meier). A P-value 
< 0.05 was considered significant. Given the study’s 
retrospective and case series nature, approval by the 
Institution Ethics Committee was waived.
RESULTS
A total of 125 patients who underwent trabeculectomy 
with primary mitomycin C after 1991 were evaluated. 
Eleven patients were excluded because they did not fulfill 
the inclusion criteria. The remaining 114 cases (164 eyes) 
were included.
The group of subjects consisted of 65 (57%) males and 
49 (43%) females. The total mean age was 57.36 +/- 51.14 
months, ranging from 0.5 to 168 months. The most common 
diagnosis was primary congenital glaucoma, accounting 
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for 88 of the cases. Eleven patients had AR disease, and 
five had Sturge-Weber disease. Others types of glaucoma 
included four cases of aniridia, two of Peter’s disease and 
three patients with aphakic glaucoma after cataract surgery. 
Three patients remained undiagnosed.
The mean preoperative intraocular pressure was 27.42 
+/- 5.91 mmHg in the successfully treated group and 30.89 
+/- 7.21 mmHg in the failed-treatment group (p= 0.0085, 
Student’s t-test) (Table 1). Sixty-three eyes were considered 
successfully treated (with a mean intraocular pressure of 
12.11 +/- 3.98 mmHg using an average of 0.47 topical 
glaucoma control medication) on the final visit -- an overall 
success rate of 55.26%. Forty-seven eyes (41.23%) showed 
an intraocular pressure of < 16 mm HG after surgery. The 
mean age of the subjects successfully operated on was 58.75 
+/- 49.92 months. 
The mean length of follow-up for the successfully treated 
eyes was 61.16 +/- 26.13 months (ranging from 12 to 113 
months). Forty-two eyes (37.84%) required no topical 
glaucoma control medication (absolute success), fourteen 
eyes (12.61%) required one drug and seven eyes (6.31%) 
required two or more drugs. A total of 21 successfully 
treated eyes required medication after surgery (33.34%). 
There were no topical medication data available for three 
patients (all from the failed-treatment group). Within the 
successfully treated group (63 eyes), 42 eyes had previously 
been operated upon.
The cumulative probabilities of success (Kaplan-Meier 
plot) for one eye of each patient were 90.2% at 24 months, 
78.7% at 36 months, 60.7% at 48 months and 50.8% at 60 
months (Figure 1).
Bleb revision (including needling) and/or suturelysis 
were not performed in any case from the successfully treated 
group.
 Surgical success and failure rates according to the 
preoperative intraocular pressure, age, number of previous 
surgeries and diagnosis can be seen in Tables 1, 2, 3, and 
4, respectively. There was only a statistically significant 
difference (p < 0.05) in the preoperative intraocular pressure 
analysis (p = 0.0085, Student’s t-test). The p-values for the 
others risk factors (age and previous surgery) were 0.67 and 
0.32, respectively. 
Surgical failure occurred in 51 eyes (44.73%). The 
mean age of these patients was 55.69 +/- 53.03 months. 
External blockage was the cause of failure in all cases. In 
the failed-treatment group, 40 eyes (35.09%) had previously 
been operated upon. Of the 164 eyes operated upon, 
endophthalmitis developed in eight (4.88%). The average 
time between surgery and diagnosis of endophthalmitis was 
36.96 months (ranging from 1.7 to 106 months) (Table 5).
One expulsive hemorrhage occurred during surgery, 
causing a loss of light perception in that eye. A flat anterior 
chamber was observed in five eyes (3.04%), hyphema in two 
eyes (1.21%) and bleb leak in one eye (0.6 %) (Table 6).
DISCUSSION
Childhood glaucoma is a disease that typically requires 
Figure 1 - Cumulative proportion of successΨ 
Ψ Number of patients at risk for failure at each time interval: 56 (at 24 months), 48 (at 36 months), 41 (at 48 months), 33 (at 60 months), 23 (at 72 months), 
12 (at 84 months), 6 (at 96 months), 1 (at 108 months) and 0 (at 120 months).
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Table 1 - Iintraocular pressure (IOP) follow-up
 Preoperative  
IOP MEAN SD
 1 month  
IOP MEAN SD
 1 year  
IOP MEAN SD
 2 years  
IOP MEAN SD
 Final visit  I
OP MEAN SD
Success  27.42 ± 5.91  11.05 ± 5.77  11.72 ± 4.24  11.61 ± 4.62  12.11 ± 3.98
Failure  30.89 ± 7.21  13.46 ± 7.19  12.62 ± 7.22  15.5 ± 8.63  24.6 ± 10.21
Total  28.97  12.03  11.97  12.52  17.31
p-value  0.0085*  0.0649  0.5067  0.03*  0.0000001*
* significant (p< 0.05) Student’s t test
Table 2 - Success and failure correlated with age
Status 0-12 
months
13-60 
months
61-120 
months
121-168 
months
Total
Success n 15 21 15 09 60
 % 50% 52.5% 65.22% 52.94% 60
Failure n 15 19 08 08 50
 % 50% 47.5% 34.78% 47.06% 50
Total n 30 40 23 17 110
 % 100% 100% 100% 100%
No data 
available
04
p = 0.67014 chi-square
Table 3 - Success and failure correlated with previous sur-
gery
Status Previous Surgery Total
YES NO
Success n 42 18 60
 % 38.18% 16.36% 54.55%
Failure n 40 10 50
 % 36.36% 9.09% 45.45%
Total n 82 28 110
 % 74.55% 25.45% 100%
No data available 04
p= 0.32755 chi-square
Table 4 - Success and failure correlated with diagnosis
Status CG AR SW AD PE CC Total
Success n 46 09 03 02 01 00 61
 % 53.48 81.2 60.0 50.0 50.0 0.0 55.0
Failure n 40 02 02 02 01 03 50
 % 46.52 18.8 40.0 50.0 50.0 100.0 45.0
Total n 86 11 05 04 02 03 111
 % 100.0 100.0 100.0 100.0 100.0 100.0 100.0
No data 
available
03
CG - Congenital Glaucoma; AR - Axenfeld – Rieger; SW - Sturge – We-
ber; AD – Aniridia; PE – Peters; CC - Congenital Cataract
Table 5 - Endophthalmitis following surgery
Time after surgery (months)  Number of eyes
0 - 12 03 (37.5%)
13- 24 00 (0%)
> 24 05 (62.5%)
Total 08 (100%)
Table 6 - Complications
Complication Total N= 164
Endophthalmitis 8 (4.88%)
Hyphema 2 (1.21%)
Leakage 1 (0.6%)
Flat anterior chamber 5 (3.04%)
Expulsive 1 (0.6%)
Total 17 (10.36%)
surgery as early as possible. Goniotomy and trabeculotomy 
are usually the procedures of first choice for primary 
congenital glaucoma. Both are safe and have a low incidence 
of complications.3,18 When goniotomy and trabeculotomy 
fail, trabeculectomy is the usual course of action. However, 
the success rate of initial trabeculotomy as a treatment for 
childhood glaucoma can be reduced by the presence of other 
ocular anomalies (Peters, Sturge-Weber, Aniridia, etc.) or by 
a corneal diameter of > 14 mm.16
In pediatric patients (patients less than 18 years of age), 
it has been reported that trabeculectomy without adjunctive 
antimetabolites achieves a successful outcome in 30% to 
50% of cases.5-7 The highest success rate (50%) was reported 
in a study with a relatively short follow-up (mean 15.5 
months)5. Studies with longer follow-ups report success rates 
of 30% to 35%.6,7 
In comparison to 5-fluorouracil, MMC is a more 
potent inhibitor of fibroblast proliferation and can be used 
intraoperatively, making it an attractive alternative for 
children for whom previous surgery has failed. Clinical 
studies comparing these two antifibrotic agents have 
425
CLINICS 2008;64:421-6 Efficacy and safety of trabeculectomy with mitomycin C for childhood glaucoma
Giampani Jr J et al.
demonstrated that MMC has a greater success rate and 
induces a greater reduction in the degree of intraocular 
pressure.19-22
Susanna et al17 achieved an overall success rate of 
67% with a mean follow-up of 17 months in a series of 
56 patients (79 eyes) with primary congenital glaucoma 
or developmental glaucomas treated with trabeculectomy 
and adjunctive MMC. This success rate is higher than the 
55.26% described in the present study. This discrepancy is 
likely attributable to the longer follow-up (61.16 months) 
applied in our study. Beck and associates23 described a 
success rate of 58% after a 24-month follow-up, although 
they had a large number of aphakic patients and a mean 
age of 91.2 months (7.6 years old). Among the cases that 
we studied, there were only two aphakic patients, and, as 
previously stated, the mean age was 57.36 months (4.78 
years old). Sidoti et al.24 showed a success rate of 59% in a 
case series of 29 eyes, with a mean follow-up time of 25.1 
+/- 16 months. In this paper, the 24- and 36-month life-table 
success rates for intraocular pressure control were both 59%, 
versus 90.2% at 24 months, 78.7% at 36 months, 60.7% at 
48 months and 50.8% at 60 months in our study.
In a series of 19 mitomycin C trabeculectomies, Mandal et 
al25 described an extremely high (95%) success rate. However, 
their study included only one patient under the age of one 
year, a factor that may have been instrumental in achieving 
such a superb success rate. In contrast, we had 30 patients 
who were less than one year old (including two presenting 
endophthalmitis), and this group showed a 50% success rate 
that was similar to the 42.85% success rate in patients under 
the age of one described by Susanna and associates.17 
In our study, the best success rate (65.22%) was achieved 
in the 61- to 120-month age group, though without a 
statistically significant difference when compared with the 
other age groups (p = 0.7 chi-square). Miller and Rice26 also 
demonstrated a better prognosis for surgeries performed in 
older children.
Susanna et al17 noted no difference in the success 
rate between eyes that had previously been submitted to 
glaucoma surgery and those that had not. The authors 
suggested that the results from the group that had no 
prior glaucoma surgery were skewed by the inclusion of 
eyes with poor prognoses due to conditions such as AR 
anomaly, Sturge-Weber syndrome and Aniridia. Beck et 
al23 demonstrated a lower success rate for the group that 
had prior glaucoma surgery (55% vs. 70%), but without a 
statistically significant difference. In our study, the success 
rate was also higher in the group with no previous glaucoma 
surgery (64.28% compared with 51.21%), but this difference 
was also not statistically significant (p= 0.32 chi-square). 
In our paper, there was a higher average preoperative 
intraocular pressure in the failed-treatment group (30.89 +/- 
7.21 mm Hg) than in the successfully treated group (27.42 
+/- 5.91 mm Hg) (p= 0.0085 – Student’s t-test). These data 
suggest that higher preoperative intraocular pressure are 
associated with a greater risk for surgical failure. 
Notably, in our series, the AR group demonstrated a 
better success rate (81.2%) (p= 0.031 difference between 
the percentages of success) than the primary congenital 
glaucoma group (53.48%) (p= 0.409 difference between the 
percentages). These results are even more intriguing if we 
consider that 54.54% of the eyes that had previously been 
operated on for glaucoma were successfully treated within 
this group. However, these data should be analyzed carefully 
because our study only contained a small number of patients 
with AR (n=11). Others studies with larger series may help 
to elucidate this question. 
Endophthalmitis is a major complication associated 
with trabeculectomy that has been reported in children who 
have undergone trabeculectomy with MMC27. In our study, 
eight of a total of 164 operated eyes (4.88%) developed 
endophthalmitis. Beck and associates23 reported a higher 
endophthalmitis incidence (8%), while Susanna et al.17 
reported one case in 79 eyes and Wallace and associates28 
noted one case in 16 eyes. Mandal et al.25 reported no cases 
of endophthalmitis in a series of 19 eyes. Sidoti et al.24 
described a higher incidence of infectious complications 
(10% blebitis and 7% endophthalmitis), probably due to 
the higher MMC concentration (0.5 mg/ml) utilized in their 
study. Wells et al,29 who utilized a limbus-based conjunctival 
flap, demonstrated the highest reported incidence of 
endophthalmitis (15%) in a series of 20 eyes. In adults, the 
incidence of endophthalmitis following antimetabolite use 
ranges from 2% to 9%.30-32
Like Sidoti et al.24, we observed a relatively long 
interval between surgery and the development of infectious 
complications. The majority of endophthalmitis cases 
occurred 24 months after surgery (Table 5).
None of the trabeculectomies in our study were 
performed in an inferior location or were associated with 
contact lens use.
Trabeculectomy with MMC has been associated with the 
development of chronic hypotony and vision loss in adults33. 
Hypotonic maculopathy is especially prevalent 
in young adults with pronounced myopia33, 34. In 
our series, only three eyes of a total of 114 developed 
overfiltration, and there was no ocular hypotony (intraocular 
pressure < 4 mm Hg) in these eyes. This low frequency 
was also described by other authors17, 23, 25, likely because 
children have a vigorous healing response. The downside of 
this vigorous healing response is the complete scarring of 
the filtration site.
426
CLINICS 2008;64:421-6Efficacy and safety of trabeculectomy with mitomycin C for childhood glaucoma
Giampani Jr J et al.
In conclusion, our study suffers from the limitations of 
a retrospective series that has no control group. However, 
the long-term follow-up of our patients (mean of five years 
in the successfully treated group) compared to other studies 
allows some conclusions to be drawn. Trabeculectomy 
with adjunctive mitomycin is an effective treatment for 
many pediatric glaucoma patients, including those with 
developmental anomalies such as AR disease. Bleb-related 
endophthalmitis is a serious risk related to this procedure 
in children, but its frequency is no higher than that seen 
in adults. Overfiltration and hypotonic maculopathy are 
complications rarely observed after trabeculectomy with 
adjunctive MMC treatment for primary congenital or other 
childhood glaucomas.
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